EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced that the 36 month Phase I clinical trial results for I-vation™ TA (triamcinolone acetonide) were presented today by Dr. Pravin Dugel at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Meeting. The primary objective of this study was to evaluate the safety and tolerability of the I-vation TA product in patients with diabetic macular edema (DME). Secondarily, preliminary efficacy was assessed through collection and analysis of retinal thickness and visual acuity data. The 36 month data represents the final patient follow-up required in this phase of the clinical trial.
